EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nicotinamide riboside prevents mitochondrial dysfunction in nemaline myopathy type 6

Rianne J Baelde iD, Leander A Vonk, Edgar E Nollet, Ricardo A Galli, Alexcia Fortes Monteiro, Sultan Bastu, Bornale Das, Michel van Weeghel, Bauke V Schomakers, Kasper T Vinten, Marloes van den Berg, Jolanda van der Velden und 5 weitere

Human Molecular Genetics · 12.06.2026 · 35 (12)

DOI: 10.1093/hmg/ddag023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Molecular Genetics, online erschienen am 21.06.2026. Verfasst von Rianne J Baelde und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Amsterdam UMC, location VUmc, De Boelelaan 1108, Amsterdam, HZ 1081, The Netherlands. Hauptthemen laut MEDLINE: Niacinamide, Myopathies, Nemaline, Mitochondria. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Danish Diabetes and Endocrine Academy, Novo Nordisk Foundation, European Union's Horizon Europe research and innovation program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nemaline Myopathy type 6 (NEM6) is a congenital myopathy caused by variants in Kelch-repeat-and-BTB-(POZ)-Domain-Containing-13 (KBTBD13). The majority of the NEM6 patients harbor the Dutch founding variant KBTBD13R408C (c.1222C > T, p.Arg408Cys) and experience skeletal muscle weakness and sarcomere-based hypercontractility. Histological characterization of NEM6 patient biopsies by NADH staining shows the presence of cores, suggesting mitochondrial dysfunction. We aimed to elucidate the role of mitochondrial dysfunction in NEM6 pathology and tested the ability of the NAD+ precursor nicotinamide riboside (NR) to improve mitochondrial performance. We performed a natural history study in homozygous Kbtbd13R408C-knockin mice (NEM6 mouse model) to investigate the onset and progression of mitochondrial dysfunction in NEM6. We performed high-resolution respirometry, metabolic treadmill experiments and histoenzymatic NADH and SDH stainings on cryosections. Additionally, we used multi-omics analyses to investigate impacted pathways and metabolite dysregulation and performed NR supplementation for eight weeks to prevent the onset of mitochondrial dysfunction in NEM6 mice. Throughout disease progression, NEM6 mice display decreased mitochondrial respiration, impaired metabolic performance and the presence of cores with histoenzymatic reactions. Multi-omics studies revealed that the TCA cycle is heavily impacted and that NAD+ levels are decreased throughout disease progression. We aimed to restore NAD+ levels by supplementation of NR. Remarkably, NR treatment in 1-months-old NEM6 mice, prevented the onset of mitochondrial dysfunction. In conclusion, these results provide insight in the onset and progression of mitochondrial dysfunction in NEM6 and offer proof-of-concept for NR as a therapeutic strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NiacinamideMyopathies, NemalineMitochondriaAnimalsHumansMiceMuscle, SkeletalDisease Models, AnimalNADMaleFemalePyridinium Compounds

Stichwörter der Autor:innen

Congenital myopathyMitochondriaNAD+ metabolismNemaline myopathySkeletal muscle

Substanzen

nicotinamide-beta-ribosideNiacinamideNADPyridinium Compounds

Autor:innen und Institutionen

  • Department of Physiology, Amsterdam UMC, location VUmc, De Boelelaan 1108, Amsterdam, HZ 1081, The Netherlands.
  • Amsterdam Cardiovascular Sciences institute, Amsterdam UMC, location VUmc, De Boelelaan 1108, Amsterdam, HZ 1081, The Netherlands.
  • Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark.
  • University Paris Est Créteil, Inserm, U955, IMRB, Créteil F-94010, France.
  • Laboratory Genetic Metabolic Diseases, Amsterdam UMC, location University of Amsterdam, Meibergdreef 9, Amsterdam AZ, 1105, The Netherlands.
  • Core Facility Metabolomics, Amsterdam UMC, location AMC, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

ORCID-Profile: Rianne J Baelde

Förderung

  • Danish Diabetes and Endocrine Academy
  • Novo Nordisk Foundation
  • European Union's Horizon Europe research and innovation program
  • Prinses Beatrix Spierfonds and A Foundation Building Strength for Nemaline Myopathies
  • The Netherlands Organisation for Health Research and Development
  • Amsterdam Cardiovascular Sciences Institute
  • the Van Coevorden Adriani Stichting/Vrije Universiteit
  • European Union’s Horizon Europe research and innovation program

Zitieren

APA

Baelde, R. J., Vonk, L. A., Nollet, E. E., Galli, R. A., Monteiro, A. F., Bastu, S., Das, B., van Weeghel, M., Schomakers, B. V., Vinten, K. T., van den Berg, M., van der Velden, J., Houtkooper, R. H., Voermans, N. C., Malfatti, E., Ottenheijm, C. A. C., & de Winter, J. M. (2026). Nicotinamide riboside prevents mitochondrial dysfunction in nemaline myopathy type 6. Human Molecular Genetics, 35(12). https://doi.org/10.1093/hmg/ddag023

Vancouver

Baelde RJ, Vonk LA, Nollet EE, Galli RA, Monteiro AF, Bastu S, et al. Nicotinamide riboside prevents mitochondrial dysfunction in nemaline myopathy type 6. Human Molecular Genetics. 2026;35(12). doi:10.1093/hmg/ddag023

BibTeX
@article{Baelde2026,
  author = {Baelde, Rianne J and Vonk, Leander A and Nollet, Edgar E and Galli, Ricardo A and Monteiro, Alexcia Fortes and Bastu, Sultan and Das, Bornale and van Weeghel, Michel and Schomakers, Bauke V and Vinten, Kasper T and van den Berg, Marloes and van der Velden, Jolanda and Houtkooper, Riekelt H and Voermans, Nicol C and Malfatti, Edoardo and Ottenheijm, Coen A C and de Winter, Josine M},
  title = {Nicotinamide riboside prevents mitochondrial dysfunction in nemaline myopathy type 6},
  journal = {Human Molecular Genetics},
  year = {2026},
  volume = {35},
  number = {12},
  doi = {10.1093/hmg/ddag023}
}
Kostenlos starten →